Bedrijfsoverzicht
Jasper Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to the development of therapeutics that target diseases driven by mast cells and hematopoietic stem cells. This operational focus places the company squarely within the healthcare sector, specifically the biotechnology industry, where it seeks to advance novel molecular mechanisms for treating complex medical conditions. As of the latest reporting period, the enterprise holds a market capitalization of $22.46 million and maintains a workforce of 22 employees. The combination of a relatively small market cap and a lean employee base indicates that the company is in an early-stage development phase, likely prioritizing capital allocation toward research and development rather than commercialization or large-scale operations.
Financiële gezondheid
The company reports a Net Income of $-75,801,000 and an EBITDA of $-80,527,000 for the trailing twelve months, while the Revenue (TTM) is listed as N/A. The significant negative net income relative to the reported EBITDA suggests a cost structure heavily influenced by non-operating expenses or specific financial engineering costs that are not captured in the standard operating EBITDA calculation, given the zero gross margin environment. Free Cash Flow stands at $-47,189,376, which indicates that the company is currently burning cash at a substantial rate to fund its clinical trials and operational expenses. This negative cash flow trajectory implies limited financial flexibility in the short term, necessitating reliance on existing cash reserves or external financing to sustain operations. The company operates with a Gross Margin of 0.0%, an Operating Margin of 0.0%, and a Profit Margin of 0.0%, reflecting a pre-revenue or pre-commercialization status typical for clinical-stage entities where no sales revenue has yet been generated to offset costs. In terms of liquidity, Jasper Therapeutics holds $28.69 million in cash against $1.24 million in debt, resulting in a Debt to Equity ratio of 29.75. Despite the high debt-to-equity figure, the balance sheet appears conservative regarding absolute leverage levels because the cash position significantly exceeds the total debt obligation. The Current Ratio is 2.62, indicating that the company possesses more than double the current assets required to cover its current liabilities, suggesting adequate short-term liquidity despite the lack of operational profitability. Return on Equity is recorded at -230.3% and Return on Assets at -88.2%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common characteristic of early-stage biotech firms focused on product discovery.
Waarderingsbeoordeling
Valuation metrics for Jasper Therapeutics present a complex picture due to the lack of traditional profitability measures. The P/E Ratio (TTM) is N/A and the Forward P/E is -0.48, a negative figure that arises from the negative net income and implies that traditional earnings-based valuation models are not applicable at this stage of the company's lifecycle. The Price to Book ratio is 5.42, which indicates that the market is pricing the company at a significant premium relative to its tangible book value, likely reflecting the high value placed on its intellectual property and pipeline potential rather than current assets. Since Revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at 0.06, suggesting an enterprise value that is nearly equivalent to its earnings multiple, though this metric is distorted by the deep negative earnings. The stock's price action over the last year has seen a 52-Week High of $7.19 and a 52-Week Low of $0.62, illustrating a high degree of price volatility as the asset trades well below its yearly peak. The Beta is 3.20, meaning the stock's price volatility is more than three times that of the broader market, highlighting the extreme sensitivity of the share price to market sentiment and sector-specific news.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, as the company has not yet generated consistent sales figures to calculate year-over-year percentage changes. Consequently, it is not possible to determine if earnings are growing faster or slower than revenue based on historical data, as the business model is currently in a cash-burn phase rather than a growth-through-sales phase. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%. This non-dividend status confirms that Jasper Therapeutics reinvests all available capital, including its cash reserves, back into the business to fund clinical development and regulatory pathways rather than distributing income to shareholders. The overall growth and income profile is characterized by a lack of current financial returns and dividend income, with the company's value proposition entirely dependent on the potential future success of its lead product candidate, briquilimab, and the successful navigation of clinical milestones.